InvestSMART

Vitrafy Life Sciences Limited (ASX: VFY) - Announcements

- Current share price for VFY : $2.270

ASX company news and announcements for Vitrafy Life Sciences Limited (VFY) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Vitrafy Life Sciences Limited (VFY) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Vitrafy Life Sciences Limited (VFY), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Vitrafy Life Sciences Limited (VFY)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$142 Change of Director's Interest Notice 1 Sep 2025 10:33AM $1.350 $2.270 risen by 68.15%
$142 FY25 Full Year Results Presentation - Amended 5 Aug 2025 10:38AM $1.600 $2.270 risen by 41.88%
$142 FY25 Corporate Governance Statement 5 Aug 2025 8:34AM $1.650 $2.270 risen by 37.58%
$142 FY25 Appendix 4G 5 Aug 2025 8:33AM $1.650 $2.270 risen by 37.58%
$142 FY25 Full Year Results Presentation 5 Aug 2025 8:33AM $1.650 $2.270 risen by 37.58%
$142 FY25 Appendix 4E and Annual Report 5 Aug 2025 8:32AM $1.650 $2.270 risen by 37.58%
$142 Leadership Transition at Vitrafy 5 Aug 2025 8:23AM $1.650 $2.270 risen by 37.58%
$142 Expiry of Voluntary Escrow Restrictions 31 Jul 2025 1:43PM $1.640 $2.270 risen by 38.41%
$142 Q4 FY25 Quarterly Activities Report and Appendix 4C 30 Jul 2025 8:53AM $1.600 $2.270 risen by 41.88%
$142 Appendix 4C, FY25 Annual Results and Investor Call Schedule 29 Jul 2025 8:38AM $1.620 $2.270 risen by 40.12%
$142 Notification of cessation of securities - VFY 25 Jun 2025 10:26AM $1.350 $2.270 risen by 68.15%
$142 Change of Address 30 May 2025 8:21AM $1.505 $2.270 risen by 50.83%
$142 Application for quotation of securities - VFY 15 May 2025 9:05AM $1.500 $2.270 risen by 51.33%
$142 Vitrafy Q3 FY25 Investor Presentation 2 May 2025 8:29AM $1.700 $2.270 risen by 33.53%
$142 Release of Securities from Mandatory Escrow 2 May 2025 8:28AM $1.700 $2.270 risen by 33.53%
$142 Q3 FY25 Quarterly Activities Report and Appendix 4C 29 Apr 2025 8:20AM $1.450 $2.270 risen by 56.55%
$142 Vitrafy Q3 FY25 Investor Briefing 28 Apr 2025 11:54AM $1.460 $2.270 risen by 55.48%
$142 USAISR successful Phase 1 Blood Platelet study 16 Apr 2025 8:16AM $1.230 $2.270 risen by 84.55%
$142 Notification regarding unquoted securities - VFY 15 Apr 2025 8:20AM $1.230 $2.270 risen by 84.55%
$142 Application for quotation of securities - VFY 8 Apr 2025 9:22AM $1.080 $2.270 risen by 110.19%
$142 Release of Securities from Mandatory Escrow 27 Mar 2025 8:36AM $1.300 $2.270 risen by 74.62%
$142 NWR Virtual Healthcare Conference Presentation 20 Mar 2025 8:20AM $1.300 $2.270 risen by 74.62%
$142 Vitrafy to present at NWR Virtual Healthcare Conference 19 Mar 2025 1:03PM $1.300 $2.270 risen by 74.62%
$142 Change of Director's Interest Notice 19 Mar 2025 12:42PM $1.300 $2.270 risen by 74.62%
$142 Vitrafy Awarded Industry Growth Program Grant 18 Mar 2025 1:52PM $1.353 $2.270 risen by 67.84%

76 - 100 of 128 results

Page 4 of 6

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.